Nomura Asset Management Co. Ltd. Has $20.46 Million Stock Holdings in Healthpeak Properties, Inc. $DOC

Nomura Asset Management Co. Ltd. raised its position in Healthpeak Properties, Inc. (NYSE:DOC) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,272,218 shares of the real estate investment trust’s stock after buying an additional 34,149 shares during the quarter. Nomura Asset Management Co. Ltd. owned 0.18% of Healthpeak Properties worth $20,457,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DOC. Integrated Wealth Concepts LLC grew its holdings in shares of Healthpeak Properties by 7.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 18,084 shares of the real estate investment trust’s stock worth $366,000 after purchasing an additional 1,231 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Healthpeak Properties by 110.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 121,881 shares of the real estate investment trust’s stock worth $2,463,000 after purchasing an additional 63,930 shares in the last quarter. Woodline Partners LP grew its holdings in shares of Healthpeak Properties by 41.3% during the 1st quarter. Woodline Partners LP now owns 59,103 shares of the real estate investment trust’s stock worth $1,195,000 after purchasing an additional 17,279 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Healthpeak Properties by 3.1% during the 2nd quarter. Brown Advisory Inc. now owns 46,770 shares of the real estate investment trust’s stock worth $819,000 after purchasing an additional 1,415 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Healthpeak Properties during the 2nd quarter worth $3,117,000. 93.57% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Healthpeak Properties

In other news, insider Scott R. Bohn sold 10,989 shares of Healthpeak Properties stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the sale, the insider directly owned 7,636 shares of the company’s stock, valued at approximately $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.23% of the company’s stock.

Healthpeak Properties Stock Performance

Shares of DOC stock opened at $19.01 on Tuesday. The business’s 50-day moving average price is $17.76 and its 200-day moving average price is $17.33. Healthpeak Properties, Inc. has a 12 month low of $15.70 and a 12 month high of $20.27. The firm has a market capitalization of $13.10 billion, a price-to-earnings ratio of 59.40, a PEG ratio of 2.43 and a beta of 1.05. The company has a current ratio of 2.96, a quick ratio of 2.96 and a debt-to-equity ratio of 1.15.

Healthpeak Properties (NYSE:DOC) last announced its quarterly earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The firm had revenue of $752.95 million for the quarter, compared to analyst estimates of $694.59 million. During the same period last year, the firm posted $0.46 earnings per share. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Equities research analysts forecast that Healthpeak Properties, Inc. will post 1.75 EPS for the current year.

Healthpeak Properties Announces Dividend

The company also recently declared a monthly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.1017 per share. This represents a c) dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Monday, June 15th. Healthpeak Properties’s dividend payout ratio (DPR) is presently 381.25%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DOC shares. Argus lowered Healthpeak Properties from a “buy” rating to a “hold” rating in a report on Thursday, February 5th. Scotiabank raised their price objective on Healthpeak Properties from $19.00 to $21.00 and gave the company a “sector perform” rating in a research note on Wednesday, May 27th. UBS Group raised their price objective on Healthpeak Properties from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, May 13th. Wall Street Zen raised Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, Weiss Ratings raised Healthpeak Properties from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 8th. Four analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.38.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.